ATE225185T1 - Verfahren zur behandlung von allergischem asthma - Google Patents

Verfahren zur behandlung von allergischem asthma

Info

Publication number
ATE225185T1
ATE225185T1 AT96926134T AT96926134T ATE225185T1 AT E225185 T1 ATE225185 T1 AT E225185T1 AT 96926134 T AT96926134 T AT 96926134T AT 96926134 T AT96926134 T AT 96926134T AT E225185 T1 ATE225185 T1 AT E225185T1
Authority
AT
Austria
Prior art keywords
allergic asthma
treating allergic
treating
asthma
allergic
Prior art date
Application number
AT96926134T
Other languages
English (en)
Inventor
Robert B Fick Jr
Paula M Jardieu
Monika B Schoenhoff
Steven J Shire
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24021032&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE225185(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE225185T1 publication Critical patent/ATE225185T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT96926134T 1995-07-27 1996-07-24 Verfahren zur behandlung von allergischem asthma ATE225185T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50801495A 1995-07-27 1995-07-27
PCT/US1996/012275 WO1997004807A1 (en) 1995-07-27 1996-07-24 Methods for treatment of allergic asthma

Publications (1)

Publication Number Publication Date
ATE225185T1 true ATE225185T1 (de) 2002-10-15

Family

ID=24021032

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96926134T ATE225185T1 (de) 1995-07-27 1996-07-24 Verfahren zur behandlung von allergischem asthma

Country Status (16)

Country Link
EP (1) EP0841946B2 (de)
JP (1) JP4153560B2 (de)
CN (2) CN101172100A (de)
AR (1) AR003468A1 (de)
AT (1) ATE225185T1 (de)
AU (1) AU715338B2 (de)
CA (1) CA2226624C (de)
DE (1) DE69624116T3 (de)
DK (1) DK0841946T4 (de)
ES (1) ES2186796T5 (de)
IL (1) IL122733A (de)
MX (1) MX9800760A (de)
PT (1) PT841946E (de)
RU (1) RU2229288C2 (de)
WO (1) WO1997004807A1 (de)
ZA (2) ZA966075B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6630140B1 (en) * 1998-03-10 2003-10-07 The Children's Hospital Of Philadelphia Compositions and methods for treatment of asthma
US6299875B1 (en) * 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
PT1324776E (pt) * 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
WO2004041862A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1558647B1 (de) 2002-11-08 2015-06-10 Ablynx N.V. Einzeldomaene antikörpern gegen tnf-alpha und ihre verwendungen
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
DE202006020194U1 (de) * 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
AU2008211807B2 (en) * 2007-01-29 2013-09-19 Valtion Teknillinen Tutkimuskeskus Method for producing novel IgE based reagents
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
EP2052736A1 (de) * 2007-10-26 2009-04-29 Nycomed Danmark ApS Parathyroidhormon-Formulierungen und ihre Verwendungen
CA2707032C (en) * 2007-12-21 2019-09-24 Inspiration Biopharmaceuticals, Inc. Stabilized factor ix formulations containing trehalose
DK2234600T3 (da) * 2007-12-21 2014-09-08 Hoffmann La Roche Antistofformulering
DK2279007T3 (en) 2008-04-29 2016-08-22 Ascendis Pharma Growth Disorders Div As Pegylated recombinant relations of human growth hormone
KR20110079693A (ko) 2008-10-29 2011-07-07 와이어쓰 엘엘씨 단일 도메인 항원 결합 분자의 정제 방법
EP2362767B1 (de) * 2008-10-29 2017-12-06 Ablynx N.V. Formulierungen von einzeldomänen-antigen-bindungsmolekülen
DK2512450T3 (en) 2009-12-15 2018-04-23 Ascendis Pharma Endocrinology Div A/S Dry growth hormone composition transiently bound to a polymer carrier
EP3372617B1 (de) 2010-04-02 2024-07-24 Amunix Pharmaceuticals, Inc. Bindungsfusionsproteine, bindungsfusionsproteinarzneimittelkonjugate, xten-arzneimittelkonjugate sowie verfahren zur herstellung und verwendung davon
CN102533704A (zh) * 2010-12-30 2012-07-04 上海雅心生物技术有限公司 即配即用型的胰蛋白酶制剂
CA2830806C (en) * 2011-03-31 2020-05-12 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
PE20191242A1 (es) * 2011-10-25 2019-09-16 Prothena Biosciences Ltd Formulaciones de anticuerpo y metodos
CN114288254A (zh) 2013-09-27 2022-04-08 韩美药品株式会社 长效人生长激素缀合物的制剂
CN104707146B (zh) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
US10799563B2 (en) 2014-11-18 2020-10-13 Ascendis Pharma Endocrinology Division Polymeric hGH prodrugs
PL3220892T3 (pl) 2014-11-21 2022-01-31 Ascendis Pharma Endocrinology Division A/S Postacie dawkowane długo działającego hormonu wzrostu
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
AU2018263868A1 (en) 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
PL3639845T3 (pl) * 2017-07-25 2023-10-23 Jiangsu Hengrui Medicine Co., Ltd. Kompozycja farmaceutyczna zawierająca kompleks białka il-15 i jej zastosowania
EP3749362A1 (de) * 2018-02-09 2020-12-16 F. Hoffmann-La Roche AG Therapeutische und diagnostische verfahren für mastzellvermittelte entzündliche erkrankungen
CN110732023B (zh) * 2018-07-18 2023-06-16 江苏恒瑞医药股份有限公司 一种her2抗体药物组合物及其用途
CN113015748B (zh) 2018-10-31 2025-12-12 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
SG11202108735QA (en) 2019-03-04 2021-09-29 Ascendis Pharma Endocrinology Div A/S Long-acting growth hormone dosage forms with superior efficacy to daily somatropin
CN113827717A (zh) * 2020-06-23 2021-12-24 三生国健药业（上海）股份有限公司 抗her2单克隆抗体冻干制剂及制备方法
TWI896700B (zh) 2020-07-10 2025-09-11 大陸商上海濟煜醫藥科技有限公司 一種抗IgE的工程化抗體及其應用
TW202409078A (zh) * 2022-07-18 2024-03-01 中國大陸商蘇州創勝醫藥集團有限公司 穩定之包含抗gremlin1抗體的藥物製劑

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
AU616916B2 (en) * 1987-11-20 1991-11-14 Kissei Pharmaceutical Co. Ltd. 4h-quinolizin-4-one compounds exhibiting therapeutic activities
WO1989006138A1 (en) * 1987-12-31 1989-07-13 Tanox Biosystems, Inc. UNIQUE ANTIGENIC EPITOPES ON IgE-BEARING B LYMPHOCYTES
US5011676A (en) * 1990-03-27 1991-04-30 Thomas Jefferson University Method to directly radiolabel antibodies for diagnostic imaging and therapy
US5290764A (en) * 1992-01-14 1994-03-01 The Dupont Merck Pharmaceutical Company Stabilization of active plasminogen activator inhibitor-1
AU3923293A (en) * 1992-03-20 1993-10-21 Immunet Human monoclonal antibodies and methods for human monoclonal antibody production
JPH07118168A (ja) * 1993-10-19 1995-05-09 Tomoyasu Ra ＩｇＥ産生抑制剤
EP1452542A3 (de) * 1992-09-24 2007-05-02 Novartis AG Umgestaltete humane monoklonale Antikörper gegen IgE
DE4344824C1 (de) * 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.

Also Published As

Publication number Publication date
IL122733A (en) 2001-09-13
ZA966075B (en) 1998-01-19
DK0841946T4 (da) 2009-02-16
MX9800760A (es) 1998-04-30
PT841946E (pt) 2003-02-28
JP4153560B2 (ja) 2008-09-24
ES2186796T3 (es) 2003-05-16
CN101172099A (zh) 2008-05-07
AU715338B2 (en) 2000-01-20
ZA966240B (en) 1998-01-23
CN101172099B (zh) 2012-02-15
JPH11510172A (ja) 1999-09-07
CA2226624A1 (en) 1997-02-13
DE69624116D1 (de) 2002-11-07
RU2229288C2 (ru) 2004-05-27
EP0841946B1 (de) 2002-10-02
DK0841946T3 (da) 2003-02-10
CN101172100A (zh) 2008-05-07
AU6638196A (en) 1997-02-26
DE69624116T2 (de) 2003-06-18
AR003468A1 (es) 1998-08-05
IL122733A0 (en) 1998-08-16
DE69624116T3 (de) 2009-07-09
EP0841946B2 (de) 2008-10-15
EP0841946A1 (de) 1998-05-20
WO1997004807A1 (en) 1997-02-13
ES2186796T5 (es) 2009-04-01
CA2226624C (en) 2013-07-16

Similar Documents

Publication Publication Date Title
DE69624116D1 (de) Verfahren zur behandlung von allergischem asthma
DE69603838D1 (de) Verfahren zur behandlung von gasen
DE69625690D1 (de) Verfahren zur vorbeugung und behandlung von allergien
DE69701714D1 (de) Verfahren zur behandlung von glassubstraten
DE69425372D1 (de) Verfahren zur behandlung endo-ostealer materialien
DE69331469D1 (de) Verfahren zur behandlung von abfällen
DE69726289D1 (de) Verfahren und zusammensetzung zur behandlung von substraten bezüglich benetzbarkeit
DE69218202D1 (de) Verfahren zur behandlung von fluoroaluminosilikatgläsern
DE69529768D1 (de) Verfahren und herstellung zur hydroverwirrung von vliesstoffen
DE69426970D1 (de) Verfahren zur Behandlung einer Ölquelle
DE59504072D1 (de) Verfahren zur herstellung von esterquats
EP0820467A4 (de) Verfahren zur behandlung von augenkrankheiten
DE69507500D1 (de) Verfahren zur behandlung von kunststoffgiessformen
DE69918306T2 (de) Verfahren und vorrichtung zur behandlung von arrythmien
DE69624625D1 (de) Verfahren und Vorrichtung zur Behandlung von Organohalogenkomponenten
DE59810532D1 (de) Verfahren zur behandlung von cellulosischen formkörpern
DE69417018D1 (de) Verfahren zur behandlung von teilchenmaterial
DE69526796D1 (de) Verfahren zur inhibierung von pflanzenkrankheiten
DE69613446D1 (de) Verfahren zur Behandlung von wässerigem Strom
DE69814467D1 (de) Verfahren zur prophylaktischen behandlung von mastitis
ATE232919T1 (de) Zusammensetzung zur behandlung von wäsche sowie verfahren hierfür
ATE191453T1 (de) Verfahren zur herstellung von aminoethylethanolamin und/oder hydroxyethylpiperazin
DE69518824D1 (de) Verfahren zur behandlung von bremsscheiben
ATE371453T1 (de) Verfahren zur behandlung von okularen neovaskularen erkrankungen
DE69609082D1 (de) Verfahren zur behandlung von abfällen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0841946

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 0841946

Country of ref document: EP